NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma Article

cited authors

  • Lee, Eudocia Q; Zhang, Peixin; Wen, Patrick Y; Gerstner, Elizabeth R; Reardon, David A; Aldape, Kenneth D; deGroot, John F; Pan, Edward; Raizer, Jeffrey J; Kim, Lyndon J; Chmura, Steven J; Robins, H Ian; Connelly, Jennifer M; Battiste, James D; Villano, John L; Wagle, Naveed; Merrell, Ryan T; Wendland, Merideth M; Mehta, Minesh P

fiu authors

publication date

  • June 15, 2020

keywords

  • ANGIOGENESIS
  • ANGIOPOIETIN-2
  • CRITERIA
  • II TRIAL
  • INHIBITION
  • Life Sciences & Biomedicine
  • MATRIX METALLOPROTEASE-2
  • NORMALIZES TUMOR VASCULATURE
  • Oncology
  • PATTERNS
  • RELAPSE
  • SURVIVAL
  • Science & Technology
  • angiogenesis
  • angiopoietin
  • bevacizumab
  • glioblastoma
  • trebananib

Digital Object Identifier (DOI)

start page

  • 2821

end page

  • 2828

volume

  • 126

issue

  • 12